Setting the New Standard
at AAIC 2025
Discover how Standard BioTools is advancing neurodegeneration research through precision proteomics.
Booth 834 l July 27–31
Advancing discovery through precision proteomics
We’re setting the new standard for protein analysis, enabling researchers worldwide to unlock critical insights into Alzheimer’s disease, dementia and other neurodegenerative conditions with unprecedented scale and precision. Our innovative platforms empower the scientific community to decode complex protein networks, identify novel biomarkers and accelerate the path from discovery to therapeutic breakthroughs.
Don’t miss our Product Theater
Uncovering Protein Biology of Neurodegeneration
at Scale: What the Global Neurodegeneration Proteomics Consortium Has Learned (so far) from SomaScan Proteomics Across Multiple Cohorts
Speakers
• Farhad Imam, Gates Ventures
• Clare Paterson, StandardBioTools
• Jacob Vogel, Lund University
Tuesday, July 29 l 1:05–1:45 pm
Stage #2 (in front of aisle 1600 in the exhibit hall)
Uncovering Protein Biology of Neurodegeneration at Scale: What the Global Neurodegeneration Proteomics Consortium Has Learned (so far) from SomaScan Proteomics Across Multiple Cohorts
Speakers
Farhad Imam and Varsha Krish, Gates Ventures
Tuesday, July 29 l 1:05–1:45 pm
Stage #2 (in front of aisle 1,600 in the exhibit hall)
What to expect from the session
The Global Neurodegeneration Proteomics Consortium (GNPC) represents a groundbreaking public-private partnership that has assembled one of the world’s largest SomaScan™ Assay proteomic datasets. This product feature will showcase transformative findings from the GNPC, including:
- Discovery of novel protein signatures for predicting major forms of dementia and neurodegenerative conditions
- Identification of multiple underlying pathologies through comprehensive protein profiling
- Mechanistic insights derived from complex protein network analysis
- Large-scale proteomic findings across diverse patient cohorts
Visit our booth
Discover the future of proteomic research. Stop by our booth to explore how Standard BioTools™ proteomic solutions can accelerate your neurodegeneration research. Our team of experts will be on hand to demonstrate:
- Case studies showcasing breakthrough discoveries in neurodegeneration
- Personalized consultations on integrating proteomics into your research pipeline
Whether you’re focused on biomarker discovery, drug target identification or unraveling disease mechanism pathways, connect with our scientists to discover how our solutions can accelerate your research and support your next breakthrough.
Learn more about dementia risk following weight loss in type 2 diabetes
at our poster session
Monday, July 28 from 7:30 am–4:15 pm (poster #108444)
Using proteomics to advance understanding of Alzheimer’s disease
Defining standards
Our industry-leading proteomic and multi-omic solutions that scale
Every marker, all at once
Our industry-leading proteomic and multi-omic solutions that scale
High-resolution spatial proteomics
Highest dynamic range and throughput
Ultrahigh-plex precision proteomics
Enable 11,000 protein measurements with unparalleled reproducibility
Interested in talking with an expert?
For Research Use Only. Not for use in diagnostic procedures. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2025 Standard BioTools Inc. All rights reserved.